Phase I trial data for remyelinating antibody in MS released

[MSUK]

Acorda Therapeutics has today announced safety and tolerability data from a Phase 1 clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis. The trial, which followed participants for up to six months after receiving a single dose of rHIgM22, found no dose-limiting toxicities at any of the five dose levels studied. Based on this, the Company intends to advance clinical development of rHIgM22..... Read More - http://www.ms-uk.org/emergingtherapies

[carolsue]

Science magazine has an informative article about so-called natural antibodies, including rHIgM22. Fascinating. And reminds me that we understand so so little about the immune system! http://www.sciencemag.org/content/347/6226/1058.full